CYDY
CytoDyn Inc.
OTC Markets OTCQBUSDEQUITY
DELAYED
Last price
0.21
■ 0.00 (0.00%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
0.21
Prev close
0.21
Day high
0.21
Day low
0.20
Volume
410.69K
Market cap
—
P/E (TTM)
—
52W range
0.18 – 0.40
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
+10.53%
+11.9%
1M
0.00%
-3.7%
3M
-40.00%
-43.1%
6M
-19.23%
-30.3%
YTD
-25.00%
-37.3%
1Y
-27.59%
-47.6%
3Y
+5.00%
-69.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $266.00K | — |
| Operating revenue | $0 | $0 | $0 | $266.00K | — |
| Cost of revenue | — | $0 | $20.63M | $53.00K | — |
| Gross profit | — | $0 | -$20.63M | $213.00K | — |
| Research & development | -$16.92M | $7.24M | $2.63M | $27.04M | -333.7% |
| Selling, general & admin | $7.26M | $10.82M | $17.14M | $44.30M | -32.9% |
| Total operating expense | -$9.66M | $18.06M | $19.94M | $145.62M | -153.5% |
| Operating income | $9.66M | -$18.06M | -$40.58M | -$145.40M | +153.5% |
| Net interest income | -$5.47M | -$18.17M | -$30.50M | -$61.56M | +69.9% |
| Pre-tax income | $3.75M | -$49.84M | -$79.82M | -$210.82M | +107.5% |
| Tax provision | $0 | $0 | $0 | $0 | — |
| Net income | $3.75M | -$49.84M | -$79.82M | -$210.82M | +107.5% |
| Basic EPS | 0.00 | -0.05 | -0.10 | -0.31 | +100.0% |
| Diluted EPS | 0.00 | -0.05 | -0.10 | -0.31 | +100.0% |
| EBIT | $8.58M | -$44.11M | -$73.07M | -$195.75M | +119.4% |
| EBITDA | $8.59M | -$44.08M | -$72.90M | -$194.97M | +119.5% |
| Basic shares | 1.21B | 969.51M | 836.53M | 676.90M | +24.4% |
| Diluted shares | 1.24B | 969.51M | 836.53M | 676.90M | +28.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $11.90M | $3.11M | $2.54M | $4.23M | +282.7% |
| Cash & short-term investments | $11.90M | $3.11M | $2.54M | $4.23M | +282.7% |
| Inventory | — | — | — | $17.93M | — |
| Total current assets | $17.88M | $10.81M | $10.80M | $10.52M | +65.3% |
| Property, plant & equipment | — | — | — | $609.00K | — |
| Goodwill & intangibles | — | — | $0 | $132.00K | — |
| Total assets | $18.05M | $11.14M | $11.29M | $29.18M | +62.1% |
| Total current liabilities | $70.52M | $84.18M | $119.80M | $123.16M | -16.2% |
| Current debt | $27.20M | $29.79M | $34.42M | $36.24M | -8.7% |
| Long-term debt | — | — | $714.00K | — | — |
| Total debt | $27.34M | $30.08M | $35.55M | $36.80M | -9.1% |
| Total liabilities | $114.09M | $127.89M | $120.79M | $123.58M | -10.8% |
| Retained earnings | -$887.79M | -$891.53M | -$841.69M | -$766.13M | +0.4% |
| Shareholder equity | -$96.04M | -$116.76M | -$109.50M | -$94.40M | +17.7% |
| Working capital | -$52.64M | -$73.37M | -$108.99M | -$112.65M | +28.3% |
| Net tangible assets | -$96.04M | -$116.76M | -$109.50M | -$94.53M | +17.7% |
| Shares issued | 1.25B | 1.06B | 919.05M | 720.03M | +18.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $3.75M | -$49.84M | -$79.82M | -$210.82M | +107.5% |
| Depreciation & amortisation | $18.00K | $29.00K | $175.00K | $781.00K | -37.9% |
| Stock-based compensation | $1.61M | $2.42M | $4.28M | $6.24M | -33.3% |
| Change in working capital | -$16.17M | $11.66M | -$1.20M | -$4.78M | -238.7% |
| Operating cash flow | -$8.77M | -$10.98M | -$25.11M | -$77.72M | +20.2% |
| Investing cash flow | $0 | $0 | $0 | $0 | — |
| Dividends paid | — | — | — | $0 | — |
| Financing cash flow | $10.85M | $11.75M | $29.93M | $48.01M | -7.6% |
| Free cash flow | -$8.77M | -$10.98M | -$25.11M | -$77.72M | +20.2% |
| End cash position | $11.90M | $9.81M | $9.05M | $4.23M | +21.3% |
| Line item | 2026-02-28 | 2025-11-30 | 2025-05-31 | 2025-02-28 | 2024-11-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $4.65M | $3.30M | $3.23M | $2.49M | $1.41M | +40.8% |
| Selling, general & admin | $1.65M | $1.80M | $1.85M | $1.52M | $2.30M | -8.1% |
| Total operating expense | $6.30M | $5.10M | $5.07M | $4.00M | $3.71M | +23.6% |
| Operating income | -$6.30M | -$5.10M | -$5.07M | -$4.00M | -$3.71M | -23.6% |
| Net interest income | -$2.23M | -$594.00K | -$890.00K | -$1.08M | -$1.14M | -275.3% |
| Pre-tax income | -$4.69M | -$22.61M | -$5.96M | -$4.76M | -$4.77M | +79.3% |
| Tax provision | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$4.69M | -$22.61M | -$5.96M | -$4.76M | -$4.77M | +79.3% |
| Net income to common | -$5.05M | -$22.61M | -$6.33M | -$5.12M | -$4.77M | +77.6% |
| Basic EPS | 0.00 | -0.02 | — | 0.00 | 0.00 | +100.0% |
| Diluted EPS | 0.00 | -0.02 | — | 0.00 | 0.00 | +100.0% |
| EBIT | -$4.08M | -$21.96M | -$4.94M | -$3.50M | -$3.49M | +81.4% |
| EBITDA | -$4.07M | -$21.96M | -$4.94M | -$3.50M | -$3.49M | +81.5% |
| Basic shares | 1.28B | 1.26B | — | 1.23B | 1.22B | +1.1% |
| Diluted shares | 1.28B | 1.26B | — | 1.23B | 1.22B | +1.1% |
| Line item | 2026-02-28 | 2025-11-30 | 2025-05-31 | 2025-02-28 | 2024-11-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $15.65M | $4.98M | $11.90M | $16.40M | $21.34M | +214.2% |
| Cash & short-term investments | $15.65M | $4.98M | $11.90M | $16.40M | $21.34M | +214.2% |
| Total current assets | $18.44M | $8.84M | $17.88M | $20.98M | $24.63M | +108.6% |
| Total assets | $18.50M | $8.94M | $18.05M | $21.19M | $24.88M | +107.0% |
| Total current liabilities | $50.43M | $85.11M | $70.52M | $70.56M | $70.63M | -40.8% |
| Current debt | — | $27.20M | $27.20M | $27.14M | $28.53M | — |
| Long-term debt | $27.20M | — | — | — | — | — |
| Total debt | $27.23M | $27.27M | $27.34M | $27.32M | $28.74M | -0.1% |
| Total liabilities | $122.78M | $128.68M | $114.09M | $114.17M | $114.27M | -4.6% |
| Retained earnings | -$920.62M | -$915.93M | -$887.79M | -$881.83M | -$877.07M | -0.5% |
| Shareholder equity | -$104.29M | -$119.75M | -$96.04M | -$92.98M | -$89.39M | +12.9% |
| Working capital | -$31.99M | -$76.27M | -$52.64M | -$49.58M | -$45.99M | +58.1% |
| Net tangible assets | -$104.29M | -$119.75M | -$96.04M | -$92.98M | -$89.39M | +12.9% |
| Shares issued | 1.36B | 1.27B | 1.25B | 1.23B | 1.22B | +7.3% |
| Line item | 2026-02-28 | 2025-11-30 | 2025-05-31 | 2025-02-28 | 2024-11-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$4.69M | -$22.61M | -$5.96M | -$4.76M | -$4.77M | +79.3% |
| Depreciation & amortisation | $4.00K | $5.00K | $4.00K | $5.00K | $4.00K | -20.0% |
| Stock-based compensation | $445.00K | $183.00K | $599.00K | $340.00K | $537.00K | +143.2% |
| Change in working capital | -$2.91M | $17.77M | -$369.00K | -$326.00K | $608.00K | -116.4% |
| Operating cash flow | -$5.52M | -$4.35M | -$5.66M | -$4.96M | -$3.59M | -26.9% |
| Investing cash flow | — | — | $0 | $0 | $0 | — |
| Financing cash flow | $16.19M | $0 | $1.17M | $21.00K | $0 | — |
| Free cash flow | -$5.52M | -$4.35M | -$5.66M | -$4.96M | -$3.59M | -26.9% |
| End cash position | $15.65M | $4.98M | $11.90M | $16.40M | $21.34M | +214.2% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.20
+6.06% from price
SMA 20
0.19
+7.69% from price
SMA 50
0.22
-5.49% from price
SMA 100
0.27
-22.02% from price
SMA 200
0.27
-22.37% from price
EMA 12
0.20
+4.96% from price
EMA 26
0.20
+2.56% from price
EMA 50
0.22
-5.56% from price
RSI (14)
54.7
Neutral
MACD (12,26,9)
-0.00
Hist 0.00
ATR (14)
0.01
4.42% of price
Realised vol 30D
51.3%
Annualised
Bollinger upper
0.21
20, 2σ
Bollinger lower
0.18
20, 2σ
50 / 200 cross
Death
0.22 vs 0.27
Trend bias
Below 200
-22.37%
Risk profile
Beta vs SPY
0.28
Less volatile than market
Correlation to SPY
0.05
Largely independent
Realised vol 30D
51.3%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-48.6%
Peak to trough
Max drawdown 5Y
-95.5%
Peak to trough
ATR 14
0.01
4.42% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer’s Disease
GlobeNewswire · 72d ago
Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
Business Wire · 80d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.